Company Encyclopedia
View More
name
Vaxart
VXRT.US
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform in the United States. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral.
1.946 T
VXRT.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking142/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-106.52%E
    • Profit Margin-34.21%E
    • Gross Margin-4.88%E
  • Growth ScoreA
    • Revenue YoY784.27%A
    • Net Profit YoY29.91%B
    • Total Assets YoY25.39%A
    • Net Assets YoY-60.91%E
  • Cash ScoreB
    • Cash Flow Margin-292.30%D
    • OCF YoY784.27%A
  • Operating ScoreB
    • Turnover0.79B
  • Debt ScoreE
    • Gearing Ratio87.20%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Director’s Bold Move: Major Stock Purchase at Vaxart

    Director Elaine Heron purchased 40,000 shares of Vaxart (VXRT) stock, valued at $15,767, indicating confidence in the company's future. Vaxart recently partnered with Dynavax, extending its cash runway into 2027, and reported positive Phase I results for its norovirus vaccine. Despite challenges like a stop work order from BARDA and delays in the norovirus trial, Vaxart is focused on advancing its vaccine candidates. TipRanks' AI Analyst rates VXRT as Neutral due to financial performance challenges and ongoing losses.

    Tip Ranks·
    US
    VXRT
    +2.21%
    Tip Ranks·
    US
    VXRT
    +2.21%

    Dir Salkind Buys 50,000 ($127.5K) Of Upexi Inc [UPXI]

    Salkind Gene Z Director of Upexi Inc [UPXI] filed a Form 4 on November 21, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:Date11/20/25TransactionPurchaseShares50,000Price$2.55Value$127,500Ending Holdings: 218,750 - IndirectFor a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.

    Reuters·
    US
    UPXI
    -2.06%
    Reuters·
    US
    UPXI
    -2.06%

    Vaxart Director Elaine J. Heron Reports Acquisition of Common Shares

    Elaine J. Heron, Director of Vaxart Inc., reported acquiring common shares of the company. The information was published via EDGAR by Vaxart Inc. on November 21, 2025. This brief is AI-generated by Public Technologies and is not financial advice.

    Reuters·
    US
    VXRT
    +2.21%
    Reuters·
    US
    VXRT
    +2.21%

    Vaxart’s Strategic Moves and Financial Highlights

    Vaxart reported Q3 earnings with revenue rising to $72.4M, driven by government contracts, but a net loss of $8.1M. Key highlights include a $700M collaboration with Dynavax for a COVID-19 oral vaccine, completion of a 5,400-participant Phase 2b trial, and promising Phase 1 results for a norovirus vaccine. Vaxart is exploring partnerships for its norovirus, HPV, and flu vaccines, with a cash runway into Q2 2027.

    Tip Ranks·
    US
    VXRT
    +2.21%
    Tip Ranks·
    US
    VXRT
    +2.21%

    Vaxart | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 72.41 M

    LB filings·
    US
    VXRT
    +2.21%
    LB filings·
    US
    VXRT
    +2.21%
    © 2025 Longbridge｜Disclaimer